Veracyte, Inc. (VCYT) Stock Analysis & Investment Frameworks
Veracyte, Inc. (VCYT) stock analysis on Invetso. Review Veracyte, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Veracyte, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
Veracyte, Inc. Key Financial Metrics
- Market Cap: $3.85B
- Revenue: $517.14M
- P/E Ratio: 57.75
- ROE: 8.64%
- ROIC: 6.70%
- Dividend Yield: N/A
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte, Inc. Investment Frameworks
Invetso analyzes Veracyte, Inc. (VCYT) across the following frameworks:
- Veracyte, Inc. 10Y Growth Potential
- Veracyte, Inc. Scenario Analysis
- Veracyte, Inc. Risks & Opportunities
- Veracyte, Inc. Economic Moat
- Veracyte, Inc. Business Model
- Veracyte, Inc. Management
- Veracyte, Inc. SWOT Analysis
- Veracyte, Inc. Porter's 5 Forces
- Veracyte, Inc. PESTLE Analysis
- Veracyte, Inc. ESG Analysis